Expert review of vaccines

Keyphrases

Publications

volume 23, number 1, 2024

Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Shingo Masuda, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Hiroshi Kamura, Haruki Imura, Hiroki Inoue, Suguru Matsuzaka, Yukihiro Sugimoto, Osamu Kuwamitsu, Iori Motohashi, Toru Morikawa, Rentaro Oda, Yuiko Hoshina, Takashi Matono, Osamu Teshigahara, Eiichiro Sando, Sadaharu Asami, Satoshi Kudo, Noboru Akizuki, Yoshikazu Muto, Tomoichiro Hayakawa, Tomoo Kishaba, Yasuji Ohara, Yoshinao Kubo, Motoi Suzuki, Konosuke Morimoto
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert review of vaccines 23 (1) (2024)
Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson
Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. Expert review of vaccines 23 (1) (2024)
Guilhem Richard, Nicole Ruggiero, Gary D Steinberg, William D Martin, Anne Searls De Groot
Neoadjuvant personalized cancer vaccines: the final frontier? Expert review of vaccines 23 (1) (2024)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Shingo Masuda, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Hiroshi Kamura, Haruki Imura, Hiroki Inoue, Suguru Matsuzaka, Yukihiro Sugimoto, Osamu Kuwamitsu, Iori Motohashi, Toru Morikawa, Rentaro Oda, Yuiko Hoshina, Takashi Matono, Osamu Teshigahara, Eiichiro Sando, Sadaharu Asami, Satoshi Kudo, Noboru Akizuki, Yoshikazu Muto, Tomoichiro Hayakawa, Tomoo Kishaba, Yasuji Ohara, Yoshinao Kubo, Motoi Suzuki, Konosuke Morimoto
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert review of vaccines 23 (1) (2024)
Syamala R Thimmiraju, Jason T Kimata, Jeroen Pollet
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses. Expert review of vaccines 23 (1) (2024)
Alexander Domnich, Andrea Orsi, Alessio Signori, Maria Chironna, Ilaria Manini, Christian Napoli, Caterina Rizzo, Donatella Panatto, Giancarlo Icardi
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection. Expert review of vaccines 23 (1) (2024)
Guilhem Richard, Nicole Ruggiero, Gary D Steinberg, William D Martin, Anne Searls De Groot
Neoadjuvant personalized cancer vaccines: the final frontier? Expert review of vaccines 23 (1) (2024)
Sheema Mir, Mohammad Mir
The mRNA vaccine, a swift warhead against a moving infectious disease target. Expert review of vaccines 23 (1) (2024)
James J Bull, Scott L Nuismer, Christopher H Remien, Megan E Griffiths, Morie A Gertz
Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect. Expert review of vaccines 23 (1) (2024)
James J Bull, Scott L Nuismer, Christopher H Remien, Megan E Griffiths, Morie A Gertz
Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect. Expert review of vaccines 23 (1) (2024)
Xiang Guo, Juan Li, Jing Qiu, Rui Zhang, Jia Ren, Zhuoying Huang, Zhi Li, Xiufang Liang, Fang Lan, Juan Chen, Fang Huang, Xiaodong Sun
Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study. Expert review of vaccines 23 (1) (2024)
Alberto San Francisco Ramos, Carolina Liu Sanchez, Tatiana Bovill Rose, David Smith, Natasha Thorn, Eva Galiza, Thahmena Miah, Jennifer Pearce, Cecilia Hultin, Catherine Cosgrove, Yingfen Hsia, Paul T Heath
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis. Expert review of vaccines 23 (1) (2024)
Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data. Expert review of vaccines 23 (1) (2024)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Shingo Masuda, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Hiroshi Kamura, Haruki Imura, Hiroki Inoue, Suguru Matsuzaka, Yukihiro Sugimoto, Osamu Kuwamitsu, Iori Motohashi, Toru Morikawa, Rentaro Oda, Yuiko Hoshina, Takashi Matono, Osamu Teshigahara, Eiichiro Sando, Sadaharu Asami, Satoshi Kudo, Noboru Akizuki, Yoshikazu Muto, Tomoichiro Hayakawa, Tomoo Kishaba, Yasuji Ohara, Yoshinao Kubo, Motoi Suzuki, Konosuke Morimoto
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert review of vaccines 23 (1) (2024)
Alexander Domnich, Andrea Orsi, Alessio Signori, Maria Chironna, Ilaria Manini, Christian Napoli, Caterina Rizzo, Donatella Panatto, Giancarlo Icardi
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection. Expert review of vaccines 23 (1) (2024)
Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson
Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. Expert review of vaccines 23 (1) (2024)
Xiang Guo, Juan Li, Jing Qiu, Rui Zhang, Jia Ren, Zhuoying Huang, Zhi Li, Xiufang Liang, Fang Lan, Juan Chen, Fang Huang, Xiaodong Sun
Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study. Expert review of vaccines 23 (1) (2024)
Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer
Multiple antigen presenting system (MAPS): state of the art and potential applications. Expert review of vaccines 23 (1) (2024)
Xuanxuan Zhang, Jialu Zhang, Si Chen, Qian He, Yu Bai, Jianyang Liu, Zhongfang Wang, Zhenglun Liang, Ling Chen, Qunying Mao, Miao Xu
Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines. Expert review of vaccines 23 (1) (2024)
Sheema Mir, Mohammad Mir
The mRNA vaccine, a swift warhead against a moving infectious disease target. Expert review of vaccines 23 (1) (2024)
Daisuke Kurai, Akiko Mizukami, Victor Preckler, Frederik Verelst, Daniel Molnar, Taizo Matsuki, Yufan Ho, Ataru Igarashi
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis. Expert review of vaccines 23 (1) (2024)
Viravarn Luvira, Punnee Pitisuttithum
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine. Expert review of vaccines 23 (1) (2024)
Mitsuhiro Nagano, Kazumasa Kamei, Hiroyuki Matsuda, Chihiro Takahashi, Jingyan Yang, Koji Wada, Naohiro Yonemoto
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan. Expert review of vaccines 23 (1) (2024)
Viravarn Luvira, Punnee Pitisuttithum
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine. Expert review of vaccines 23 (1) (2024)
Alberto San Francisco Ramos, Carolina Liu Sanchez, Tatiana Bovill Rose, David Smith, Natasha Thorn, Eva Galiza, Thahmena Miah, Jennifer Pearce, Cecilia Hultin, Catherine Cosgrove, Yingfen Hsia, Paul T Heath
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis. Expert review of vaccines 23 (1) (2024)
Vivek P Chavda, Suneetha Vuppu, Toshika Mishra, Sathvika Kamaraj, Nikita Sharma, Swati Punetha, Anand Sairam, Dixa Vaghela, Narges Dargahi, Vasso Apostolopoulos
Combatting infectious diarrhea: innovations in treatment and vaccination strategies. Expert review of vaccines 23 (1) (2024)
Vivek P Chavda, Suneetha Vuppu, Toshika Mishra, Sathvika Kamaraj, Nikita Sharma, Swati Punetha, Anand Sairam, Dixa Vaghela, Narges Dargahi, Vasso Apostolopoulos
Combatting infectious diarrhea: innovations in treatment and vaccination strategies. Expert review of vaccines 23 (1) (2024)
Vipin M Vashishtha, Puneet Kumar
The durability of vaccine-induced protection: an overview. Expert review of vaccines 23 (1) (2024)
Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data. Expert review of vaccines 23 (1) (2024)
Vipin M Vashishtha, Puneet Kumar
The durability of vaccine-induced protection: an overview. Expert review of vaccines 23 (1) (2024)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Shingo Masuda, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Hiroshi Kamura, Haruki Imura, Hiroki Inoue, Suguru Matsuzaka, Yukihiro Sugimoto, Osamu Kuwamitsu, Iori Motohashi, Toru Morikawa, Rentaro Oda, Yuiko Hoshina, Takashi Matono, Osamu Teshigahara, Eiichiro Sando, Sadaharu Asami, Satoshi Kudo, Noboru Akizuki, Yoshikazu Muto, Tomoichiro Hayakawa, Tomoo Kishaba, Yasuji Ohara, Yoshinao Kubo, Motoi Suzuki, Konosuke Morimoto
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert review of vaccines 23 (1) (2024)
Ian McGovern, Alexandra Taylor, Aditya Sardesai, Hector Toro-Diaz, Mendel Haag
Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine. Expert review of vaccines 23 (1) (2024)
Ian McGovern, Alexandra Taylor, Aditya Sardesai, Hector Toro-Diaz, Mendel Haag
Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine. Expert review of vaccines 23 (1) (2024)
Hua Shi, Ted M Ross
Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine. Expert review of vaccines 23 (1) (2024)
Syamala R Thimmiraju, Jason T Kimata, Jeroen Pollet
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses. Expert review of vaccines 23 (1) (2024)
Guilhem Richard, Nicole Ruggiero, Gary D Steinberg, William D Martin, Anne Searls De Groot
Neoadjuvant personalized cancer vaccines: the final frontier? Expert review of vaccines 23 (1) (2024)
Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer
Multiple antigen presenting system (MAPS): state of the art and potential applications. Expert review of vaccines 23 (1) (2024)
Xuanxuan Zhang, Jialu Zhang, Si Chen, Qian He, Yu Bai, Jianyang Liu, Zhongfang Wang, Zhenglun Liang, Ling Chen, Qunying Mao, Miao Xu
Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines. Expert review of vaccines 23 (1) (2024)
Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer
Multiple antigen presenting system (MAPS): state of the art and potential applications. Expert review of vaccines 23 (1) (2024)
Daisuke Kurai, Akiko Mizukami, Victor Preckler, Frederik Verelst, Daniel Molnar, Taizo Matsuki, Yufan Ho, Ataru Igarashi
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis. Expert review of vaccines 23 (1) (2024)
Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson
Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. Expert review of vaccines 23 (1) (2024)
Hua Shi, Ted M Ross
Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine. Expert review of vaccines 23 (1) (2024)
Cody Palmer, Christiaan Dolk, Ugne Sabale, Wei Wang, Kunal Saxena
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands. Expert review of vaccines 23 (1) (2024)
Ugne Sabale, Janice Murtagh, James Cochrane, Danielle Riley, Richard Perry, Louise Heron, Paolo Bonanni, Jose Navarro Alonso, Juhani Eskola, Valerie Laigle
Assessment of the comprehensiveness of paediatric national immunisation programmes in Europe: expert validation and future perspectives. Expert review of vaccines 23 (1) (2024)
Abundio Balgos, Suad Hannawi, Wen-Li Chen, Alaa Abuquta, Linda Safeldin, Aala Hassan, Ahmad Alamadi, Louie Tirador, Anjuli May Jaen, Ralph Elvi Villalobos, Chen Mo, Zi-Jing Yue, Ying Ma, Qing-Shuang Wang, Ren-Du Wen, Zheng Yao, Jia-Ping Yu, Wen-Rong Yao, Jian-Hui Zhang, Kun-Xue Hong, Yong Liu, Jing-Xin Li
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies. Expert review of vaccines 23 (1) (2024)
Gabiria Pastore, Jacopo Polvere, Fabio Fiorino, Simone Lucchesi, Giorgio Montesi, Ilaria Rancan, Sara Zirpoli, Arianna Lippi, Miriam Durante, Massimiliano Fabbiani, Mario Tumbarello, Francesca Montagnani, Donata Medaglini, Annalisa Ciabattini
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant. Expert review of vaccines 23 (1) (2024)
Mitsuhiro Nagano, Kazumasa Kamei, Hiroyuki Matsuda, Chihiro Takahashi, Jingyan Yang, Koji Wada, Naohiro Yonemoto
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan. Expert review of vaccines 23 (1) (2024)
Cody Palmer, Christiaan Dolk, Ugne Sabale, Wei Wang, Kunal Saxena
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands. Expert review of vaccines 23 (1) (2024)
Ugne Sabale, Janice Murtagh, James Cochrane, Danielle Riley, Richard Perry, Louise Heron, Paolo Bonanni, Jose Navarro Alonso, Juhani Eskola, Valerie Laigle
Assessment of the comprehensiveness of paediatric national immunisation programmes in Europe: expert validation and future perspectives. Expert review of vaccines 23 (1) (2024)
Syamala R Thimmiraju, Jason T Kimata, Jeroen Pollet
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses. Expert review of vaccines 23 (1) (2024)